Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
15. Mai 2017 08:15 ET
|
Minerva Neurosciences, Inc.
Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseasesCompany to host conference call on May 16, 2017 at...
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
15. Mai 2017 08:00 ET
|
Minerva Neurosciences, Inc.
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3...